Suggestions
Sarah Hershey
Partner at Bain & Company
Sarah Hershey is a Partner at Bain & Company, specializing in the Private Equity practice.13 She primarily advises clients in the Consumer Products and Healthcare and Life Sciences industries, with a focus on manufacturing and supply chain topics such as co-manufacturing, packaging, distribution, and related services.1
Professional Experience and Expertise
Sarah joined Bain & Company in 2005 and has developed expertise in various areas, including:
- Commercial due diligence
- Operational due diligence
- Growth strategy
- Commercial excellence
- Cost improvement
She is also a leader in Bain's Operational Value Creation practice, specializing in margin improvement for both diligence and post-acquisition projects.1
Industry Focus
Sarah's work primarily revolves around two main industries:
-
Consumer Products: Advising clients on various aspects of their business operations and strategy.
-
Healthcare and Life Sciences: Focusing on manufacturing and supply chain topics, as well as private equity investments in the healthcare sector.12
Additional Responsibilities
Beyond her client work, Sarah is actively involved in:
- Training and recruiting teams at Bain & Company
- Serving as the head of Women@Bain in the Boston office1
Education
Sarah holds impressive academic credentials:
- MBA from the Wharton School of the University of Pennsylvania, where she was named a Palmer Scholar
- B.A. in political economics from Princeton University1
Recent Insights
Sarah has contributed to several reports and insights in the healthcare private equity sector, including:
- "Medtech: Healthcare Private Equity Deals Bounced Back to End 2022" (April 2023)
- "Healthcare Exits: Corporate Buyers Step Up" (March 2022)
- "Healthcare Private Equity in North America: Macro Trends Broaden Investment Opportunities" (March 2022)12
Sarah Hershey's LinkedIn profile can be found under the username sarah-hershey-5b9b533, confirming her role as a Partner at Bain & Company.3
Highlights
Healthcare markets in the Asia-Pacific region are maturing—and in parallel, private equity deal volume is bucking the slowdown seen in North America. Our latest report breaks down the key factors behind India’s emergence as a new hub of healthcare PE deal activity.
Although the life sciences sector continues to attract buyout activity, private equity deal value in 2023 struggled to match the levels of 2022. Our latest report breaks down four key forces shaping the investment landscape and innovation in life sciences.
